The rBC2LCN-positive subpopulation of PC-3 cells exhibits cancer stem-like properties

rBC2LCN lectin as a potential probe of early‐stage HER2‐positive breast carcinoma

“…We previously reported that the proportion of rBC2LCN‐positive cells of the human prostate carcinoma cell line PC‐3 decreased with increasing cell passages [12]. To compare the comprehensive expression profiles between the rBC2LCN‐positive and the rBC2LCN‐negative breast carcinoma cell lines, we performed DNA microarray analysis using the rBC2LCN‐positive (MCF‐7, n = 2 and T‐47D, n = 2) and the rBC2LCN‐negative (MDA‐MB‐157, n = 2 and MDA‐MB‐231, n = 2) cell lines under the same conditions illustrated in Fig.…”

“…The molecular characterization of the breast carcinoma cell lines, such as the luminal epithelial‐like and the mesenchymal/basal‐like cells, has led to the identification of novel markers for cancer diagnosis and targeted therapy [17]. Previously, we reported that as the cell passage increased, there was a decrease in the proportion of rBC2LCN‐positive cells in the human prostate carcinoma cell line PC‐3 with high expression levels of epithelial marker genes [12]. Generally, the gene expression profile is known to change according to the cell culture condition, as well as the cell culture passage.…”

“…rBC2LCN and BSA (A7638‐10G; Sigma, St. Louis, MO, USA) were labeled using the HiLyte Fluor 647 Labeling Kit‐NH2 (LK15; Dojindo, Kumamoto, Japan), as described in a previous paper [10]. Flow cytometry was performed using HiLyte Fluor 647‐conjugated rBC2LCN or HiLyte Fluor 647‐conjugated BSA, as previously described [12]. The flow cytometry data were acquired on FACSAria (BD Biosciences, Franklin Lakes, NJ, USA) and SH800Z (Sony, Tokyo, Japan) devices and were analyzed using FlowJo v10 software (BD Biosciences).…”

“…DNA microarray analysis was performed, as previously described [10,12]. Raw microarray data were submitted to the Gene Expression Omnibus at the National Center for Biotechnology Information (accession number http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139670).…”

“…We have previously reported that rBC2LCN can discriminate the undifferentiated status of human pluripotent stem cells [9,10]. In addition, rBC2LCN lectin has been shown to detect some human cancers, including breast, pancreatic, and prostate cancers [7,11,12]. Our most recent data suggested that rBC2LCN was useful for detecting a cancer stem‐like subpopulation of human prostate carcinoma PC‐3 cells [12].…”